Skip to main content

Table 1 Ongoing mortality trials with ARBs in heart failure

From: Angiotensin receptor blockers in heart failure after the ELITE II trial

    

Power primary endpoint

 

Expected

Study

Drugs

Type of patients

n

reduction (%)

Endpoints

to be concluded

Val-HeFT

Valsartan vs placebo

Symptomatic HF,

5009

20

Total mortality

2000

 

(open ACEi)

LVEF ≤ 40%

  

Morbidity

906 deaths

CHARM

Candesartan vs placebo

Symptomatic HF +

 

16-20

CV mortality/

2002

  

LVEF≤ 40, on ACEi

2550

 

HF hospitalization

 
  

LVEF≤ 40, ACEi intolerant

2000

 

(total mortality in

 
  

LVEF> 40, no ACEi

2970

 

the combined arms)

 
  1. LVEF, left ventricular ejection fraction; CV, cardiovascular; MI, myocardial infarction.